Nanox Imaging Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Revenue: $4.2 million for Q2 2026, a 37% increase from $3 million in Q2 2025.

Breakdown: $3 million from teleradiology services, $1 million from AI and software solutions, and $0.2 million from imaging systems and OEM services.

Adjusted EBITDA Loss: $11.3 million, compared to a loss of $10.4 million in Q2 2025.

GAAP Net Loss: $55.5 million, significantly higher than a loss of $14.7 million in Q2 2025, largely due to a $40.7 million impairment charge related to intangible assets.

Cash Position: $31.4 million as of June 30, 2026, down from $60 million at the end of 2025. An additional $8.5 million was raised post-quarter through an ATM program and direct offering.

2Strategic Updates and Business Highlights

Commercialization Progress:

Deployment of Nanox.ARC systems in the U.S., including the first installation in Philadelphia and an orthopedic center in Florida.

Expansion of partnerships with established imaging centers like RadNet, enhancing market presence.

10 signed commercial distribution partnerships in the U.S. to support broader market coverage.

Nanox Imaging Network: Early installations have begun generating reimbursement claims, validating the commercial opportunity.

AI Solutions: Continued advancements with new installations and pilot programs in the U.S. and India, including a successful pilot study with Cedars-Sinai.

International Expansion: Ongoing deployments in Europe and Latin America, with new distribution partnerships in Costa Rica and other regions.

3Forward Guidance and Outlook

Management expects to see the impact of recent commercialization efforts in the upcoming months, with a focus on expanding the Nanox Imaging Network and increasing utilization rates.

The company anticipates annual revenue potential of $0.5 million to $1 million per site for the Nanox Imaging Network, depending on various factors.

Cost-saving measures are projected to yield approximately $2 million in annualized savings starting in 2027.

4Bad News, Challenges, or Points of Concern

Impairment Charge: The $40.7 million impairment charge reflects a significant decline in share price and reduced revenue forecasts, raising concerns about asset valuation.

Increased Net Loss: The substantial increase in net loss highlights ongoing financial challenges, particularly in managing operational costs.

Operational Delays: Commercialization has taken longer than expected due to operational friction points, including permitting and integration challenges with imaging centers.

Cash Burn: The company is actively seeking additional capital to extend its runway, indicating potential liquidity concerns.

5Notable Q&A Insights

Impairment Assessment: Management confirmed that no further impairments are currently anticipated, but assessments will continue periodically.

Pipeline and Placements: Erez Meltzer noted several installations in Europe and the U.S., with ongoing efforts to convert evaluations into sales.

Revenue Expectations: Management indicated that traction from recent efforts should begin to reflect in revenues in the next few months.

Cost Rationalization: Guy Nathanzon was cautious about providing specific future operating expense targets but emphasized ongoing evaluations for cost reductions.

Reimbursement Pathways: The new CMS code for AI solutions is expected to facilitate commercial adoption, with early revenues already being generated from this initiative. Overall, while Nanox Imaging is making strides in commercialization and strategic partnerships, it faces significant financial challenges and operational hurdles that need to be addressed to ensure sustainable growth.